South Korean biotech Lemonex Inc. has signed a material transfer agreement (MTA) with global pharmaceutical giant Sanofi S.A. to use the Korean biotech’s drug delivery platform technologies, Lemonex said on Tuesday.
The platform, named DegradaBALL, enables the effective delivery of drug candidates into the cultured cells or lesions by loading the medication inside.
The drug delivery technology is optimized for the development of gene therapy, cancer immunotherapy, antibody therapy and synthetic drugs, Lemonex said.
DegradaBALL is more effective at maintaining the size of the particles, concentration of the loaded drugs and the stability of the delivery system at room temperature, compared with pre-existing lipid nanoparticles (LNPs) for messenger ribonucleic acid (mRNA) delivery, Lemonex added.
The MTA is a preliminary stage for an important deal such as technology transfer or joint development of the drug, Lemonex said.
“Sanofi has thoroughly verified the intellectual properties on DegradaBALL via online meetings every other week. We’re expecting the agreement will lead to a commercial licensing or joint development,” Lemonex CEO Won Cheol-hee said.
Sanofi and Lemonex started discussions on the transfer in June 2021. The contract negotiation has accelerated since Lemonex’ LEM-S401, a DegradaBALL-based small interfering (si) RNA drug candidate targeting hypertrophic scars & keloid tissue, entered into Phase I clinical trials earlier this year.
DegradaBALL doesn’t cause thrombosis and enhances immune system response, making it appropriate for vaccines, said the Lemonex CEO.
The Korean biotech has recently completed toxicity of LEM-mR203, an mRNA COVID-19 vaccine candidate, and is planning to file for phase 1 clinical trials of the drug as a booster later this year.
The Samsung Biologics headquarters in Songdo International Business District, South Korea The Life Science Fund, jointly launched by Samsung Biologics and Samsung C&T Corp., announced Wednesday it invested $15 million in US biotech firm Senda Biosciences. Samsung C&T was founded as
An SK Bioscience researcher SK Discovery Co., an intermediate holding company of South Korea’s third-largest conglomerate SK Group, will take charge of the entire biotechnology and pharmaceutical businesses at its affiliates for efficient management.According to industry officials on Thur
A researcher holds up a vial of Regkirona developed by Celltrion A string of South Korean pharmaceutical and biotech companies are waving the white flag when it comes to developing COVID-19 treatments. As the outbreak has become an endemic, a state where the virus is consistently present b
Samsung Biologics' third plant in Songdo, Incheon Samsung Group’s 150 billion won ($124 million) Life Science Fund launched last year has chosen a leading US gene therapy development company as its first investment target.Samsung C&T Corp. and Samsung Biologics Co., the joint operator
South Korea's biotech startup Novelty Nobility Inc. has signed a global license agreement for its antibody treatment candidate with a US biopharmaceutical company.Novelty Nobility said on Feb. 16 that it has agreed on the exclusive technology transfer of a monoclonal antibody (mAb) candidate,